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Abstract 
 
Objectives 
Inflammatory Breast cancer (IBC) is a rare but aggressive form of breast cancer. Its incidence and 
behaviour in the UK is poorly characterised. We collected retrospective data from hospitals in the 
UK and Ireland to describe the presentation, pathology, treatment and clinical course of IBC in the 
UK.  
 
Materials and Methods 
Patients with IBC diagnosed between 1997 -2014 at fourteen UK and Irish hospitals were identified 
from local breast unit databases. Patient characteristics, tumour pathology and stage, and details of 
surgical, systemic and radiotherapy treatment and follow-up data were collected from electronic 
patient records and medical notes. 
 
Results 
 
This retrospective review identified 445 patients with IBC accounting for 0.4-1.8% of invasive 
breast cancer cases. Median follow-up was 4.2 years. 53.2% of tumours were grade 3, 56.2% were 
oestrogen receptor positive, 31.3% were HER2 positive and 25.1% were triple negative. 20.7% of 
patients had distant metastases at presentation. Despite trimodality treatment in 86.4%, 40.1% of stage 
III patients developed distant metastases. Five-year overall survival (OS) was 61.0% for stage III and 
21.4% for stage IV patients. 
 
 
Conclusions 
 
This is the largest series of UK IBC patients reported to date. It indicates a lower incidence than in 
American series, but confirms that IBC has a high risk of recurrence with poor survival despite 
contemporary multi- modality therapy. A national strategy is required to facilitate translational 
research into this aggressive disease. 
 
Key words: Inflammatory breast cancer, Breast, Cancer, Large cohort 
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Introduction 
 
First described in 1924, inflammatory breast cancer (IBC) is a rare but aggressive form of invasive 
breast cancer [1]. US registry data indicate that IBC accounts for 2-4% of breast cancer cases but up 
to 10% of breast cancer deaths owing to the associated poor prognosis [2,3]. In other industrialised 
countries the incidence of IBC varies from 0.09-2.9% (Japan) to 0.6-2.0% (Italy ) [4,5]. No 
comparable data are available for the UK, as IBC cases are not identified within National Cancer 
Intelligence reports [6]. 
 
 
The diagnosis of IBC is based on clinical features of erythema and skin oedema with prominent 
dermal hair follicles (peau d’orange) of less than 6 months duration [7,8], and no unique 
histological identifiers [9]. Dermal lymphatic invasion (DLI) with tumour emboli is considered a 
histological hallmark, being the primary cause of the breast lymphatic obstruction seen in IBC, but 
is identified in less than 75% of IBC cases [10]. 
 
 
Clinical guidelines recommend use of aggressive primary systemic therapies; however outcomes 
remain poor with series reporting high rates of systemic recurrence and poor overall survival [9, 11, 
12]. A better understanding of the biology of IBC is clearly required [3], but clinical trial data for 
interventions in IBC are severely limited. A 2011 multidisciplinary meeting of UK specialists with 
an interest in IBC resulted in the establishment of the UK IBC consortium, [13]. Our aims are to 
establish a national mechanism for conducting research into IBC, through provision of practical 
guidelines to encourage: 1) consistent definition, 2) uniform collection of diagnostic information, 
and 3) standardisation of treatment approaches. To inform the design of future prospective and 
interventional studies, we have reviewed the incidence, pathology, treatment and outcomes of UK 
IBC patients with primary IBC (IBC in a previously normal breast) treated at thirteen UK and one 
Irish breast cancer units between 1997 and 2014.  
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Patients and Methods 
 
Breast unit databases at fourteen participating hospitals were reviewed to identify patients with  
primary invasive breast cancer documented as IBC and /or TNM stage T4d and diagnosed between 
2014 and 1997 (or as far back as records were available). Participating centres were chosen to 
represent different geographical regions: 3 centres from central England; two from London; three 
from the South; one from North England; two from Scotland; one from Wales; one from Ireland. 
Medical records were interrogated to confirm that identified cases fulfilled clinical criteria for a 
diagnosis of IBC published at the time of presentation [7-9]. Patients received treatment and follow-
up according to local protocols. The total number of breast cancer cases diagnosed at each unit 
during the record availability period was requested. Data were collected from hospital electronic 
patient records and patient case notes. Patient characteristics, imaging findings, tumour pathology, 
disease stage, and treatment received pathological response rate, time to loco-regional and distant 
disease recurrence, site of metastases, and overall survival were recorded. Follow-up data were 
censored at last clinic attendance. Hormone receptor levels equivalent to an Allred score of >2 were 
categorised as positive [14]. A complete pathological response after primary chemotherapy was 
defined as no residual invasive carcinoma within the breast (DCIS permitted) following surgery and 
no evidence of metastatic disease within resected lymph nodes. A partial response was defined as 
showing residual disease following surgery with some features of response to therapy [15].  
 
All data collections were registered and approved locally. Storage and transfer of 
anonymized data were performed according to institutional governance protocols. 
 
Statistical Analyses 
 
Summary statistics were used to describe both cohorts. Analyses were performed in STATA v11.2. 
Overall survival (OS) and distant relapse free survival (DRFS) were assessed using Kaplan-Meier 
curves and their corresponding hazard rates were evaluated using Cox proportional hazards 
model. OS and DRFS were assessed as time from date of invasive breast cancer diagnosis to death 
from any cause (OS), and to date of distant relapse or death from breast cancer (DRFS). Patients 
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who had not experienced an event at the time of analysis were censored at their date of last follow-
up. Patients with Stages III and IV at presentation were analysed separately for OS. 
 
Results 
 
 
A total of 445 patients with IBC diagnosed between1997-2014 were identified by the 14 
participating hospitals. Ten breast cancer units provided numbers of total invasive breast cancer 
cases diagnosed during the search period; the incidence of IBC at these units ranged from 0.4%-
1.8%. Full details of the hospitals involved and number of cases submitted are provided in 
Supplementary Table 1. 
 
 
Patient Characteristics 
 
Table 1 demonstrates patient demographics. Median age at diagnosis of IBC was 56 years, (range 
26-92). Data on ethnicity were available for 248 patients: 88.7% of these were white/Caucasian. 
Body mass index data were available for 160 patients (36%); median BMI at presentation was 
28.72kg/m2. (range 18.2-48.9) with 26.3% within the World Health Organisation healthy weight 
category (BMI 18.5-24.9 kg/m2), 31.9% being overweight (BMI 25.0-29.9 kg/m2) and 41.3% 
being obese (BMI ≥ 30.0 kg/m2). 
 
Presentation and Diagnostics 
 
Patient presentation details were provided for 226 cases and 19% (43) of these were treated for 
presumed infection prior to diagnosis of IBC. Sonographic results were available for 314 cases 
(Table 1).  Four patients had bilateral tumours. A measurable tumour mass was visible on initial 
imaging in 276 cases (87.9%) with a median size of 40 mm (range 5.4-145), whilst diffuse changes 
only were visible in 38 (12.1%). One hundred and forty-two tumours were multifocal (40.5%) and 
oedema was present in 250 (82.8%). All patients had a core biopsy. Skin punch biopsies were 
performed in 18 cases: 13 (72.2%) were positive for malignant cells. Abnormal axillary lymph 
nodes were seen on imaging in 301 cases (86.7%). Data on core biopsy and/or fine needle 
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aspiration of axillary lymph nodes were available for 252 cases, and 214 of these (84.9%) were 
positive for malignant cells. Evidence of distant metastases at presentation was found in 20.7% of 
patients (90/434).
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Patient demographics 
Number 
(n = 445) 
Percentage Imaging 
Number 
(n=449
#) 
Percentage 
Yea r of Dia gnos is 
      1990---2000 
      2001---2005 
      2006---2010 
      2011---2015 
      Mis s ing 
 
9 
41 
204 
191 
0 
 
2 
9.2 
45.8 
42.9 
0 
Sonogra phic a ppea ra nce 
Mea s ura ble tumour ma s s 
Diffus e cha nges only 
Mis s ing 
 
276 
38 
135 
 
87.9 
12.1 
30.1 
Multifoca l dis ea s e 
Yes 
No 
Mis s ing 
 
142 
209 
98 
 
40.5 
59.5 
21.8 
Age / yea rs 
      Media n ( ra nge) 
 
 
56 (26---92) 
 
Ethnicity 
     White/ Ca uca s ia n 
     As ia n 
     Bla ck 
     Other 
     Mis s ing 
 
220 
13 
12 
3 
197 
 
88.7 
5.2 
4.8 
1.2 
44.3 
Dia meter of tumour ma s s /mm 
Media n, (ra nge) 
Mis s ing 
 
  40 (5.4---145) 
135 
 
Oedema 
Yes 
No 
Mis s ing 
 
250 
52 
147 
 
82.8 
17.2 
32.7 Treatment of Stage III  
patients 
Number 
(n = 344) 
Percentage 
Abnorma l a xilla ry LN 
Yes 
No 
Mis s ing 
 
301 
46 
102 
 
86.7 
13.3 
22.7 
 Sys temic thera py 
Neoa djuva nt chemo 
Neoa djuva nt endocrine  
Adjuva nt chemothera py 
No s ys temic thera py 
       Mis s ing 
 
323 
9 
3 
8 
1 
 
94.2 
2.6 
0.9 
2.3 
0.3 
 n=445 percent 
Dis tant meta s ta s es  
Yes 
No 
Mis s ing 
 
90 
344 
11 
 
20.7 
79.3 
2.5 Chemothera py regimen  
Anthra cycline / Ta xa ne 
Anthra cycline/ no  
Ta xa ne/ no a nthra cyline 
Other 
Mis s ing 
 
Tra s tuzuma b (HER2+pts 
Yes 
No 
       Mis s ing 
 
199 
107 
12 
3 
5 
 
 
86 
14 
0 
 
62 
33.3 
3.7 
0.9 
1.5 
 
 
86 
14 
0 
Tumour Pathology 
Number 
(n=449#) 
Percentage 
His tologica l Type 
Ducta l ca rcinoma 
Lobula r ca rcinoma 
Mixed ducta l/ lobula r 
Other 
       Mis s ing 
 
371 
45 
6 
18 
9 
 
84.3 
10.2 
1.4 
4.1 
2 
Gra de 
1 
2 
3 
        mis s ing 
 
20 
176 
223 
30 
 
4.8 
42 
53.2 
6.7 
Brea s t Surgery 
Ma s tectomy 
Skin s pa ring  
Brea s t cons erving   
BCS with s ubs equent  
No s urgery 
        Mis s ing 
 
288 
5 
20 
3 
20 
8 
 
85.7 
1.5 
6 
0.9 
6 
2.3 
Tumour Dia meter*  
       Media n (ra nge) 
       Mis s ing/ una va ila ble 
 
24     (0--- 
120 
 
Axilla ry Surgery 
Axilla ry node clea ra nce  
Sentinel node biops y  
SNB followed by ANC 
Axilla ry s a mpling 
No a xilla ry s urgery 
       Mis s ing 
 
175 
15 
6 
7 
20 
121 
 
78.5 
6.7 
2.7 
3.1 
9 
35.2 
ER s ta tus 
Pos 
Neg 
       Mis s ing 
 
248 
193 
8 
 
56.2 
43.8 
1.8 
PR s ta tus 
Pos 
Neg 
       Mis s ing 
 
128 
207 
114 
 
38.2 
61.8 
25.4 Ra diothera py 
 Brea s t (BCS  pa tients , n=20)  
 Yes 
 No 
Mis s ing 
Ches t wa ll (ma s tectomy  
Yes 
 No 
Mis s ing 
Axilla 
Yes 
No 
Mis s ing 
Supra cla vicula r Fos s a 
Yes 
No  
       Mis s ing 
 
 
17 
0 
3 
 
255 
17 
16 
 
41 
226 
77 
 
153 
140 
51 
 
 
100 
 
15 
 
93.8 
6.3 
5.6 
 
15.4 
84.6 
22.4 
  
52.2 
47.8 
14.8 
HER2 s ta tus 
Pos 
Neg 
       Mis s ing 
 
133 
295 
21 
 
31.1 
68.9 
4.7 
ER/PR/HER2 s ta tus 
Triple nega tive** 
Not triple nega tive 
       Mis s ing 
  
107 
320 
22 
 
25.1 
74.9 
4.9 
Lymphova s cula r Inva s ion  
Yes 
No  
       Mis s ing 
 
129 
195 
125 
 
39.8 
60.2 
27.8 
Noda l s ta tus * 
Pos 
Neg 
       Mis s ing 
 
128 
237 
84 
 
35.1 
64.9 
18.7 
#
Includes 4 pa tients with bila tera l tumours 
*pos t neo---a djuva nt chemothera py in 327 ca s es ** ER/PR a nd HER 2 nega tive or ER/HER2 nega tive a nd PR unknown 
Table 1: Patient characteristics, imaging results, tumour pathology and treatment 
Tumour Pathology 
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Tumour core pathology details are presented in Table 1. Grade 3 tumours represented 53.2% of all 
cases, 56.2% were oestrogen receptor (ER) positive, and 31.1% were HER2 positive, with 25.1% 
having triple negative phenotype (ER and HER2 negative, with PR negative or unknown). Vascular 
invasion was identified in 39.8% of tumours. 
 
Treatment of non-metastatic patients 
 
Systemic therapy and response 
 
Treatment received by confirmed stage 3 patients (n=344) is summarised in Table 1. Primary 
chemotherapy was used in 94.2% of patients, with 0.9% receiving adjuvant chemotherapy. Most 
patients received anthracyline/taxane combination chemotherapy (62.0%) or another anthracyline 
based regimen (33.3%). Eighty- six per cent of HER2 positive patients received neo/adjuvant 
trastuzumab. Three patients received bevacizumab. A complete pathological response (pCR) was 
recorded in 18.1% of patients treated with primary chemotherapy (Table 2), with pCR rates in 
different biological subtypes varying as follows: ER positive/ HER2 negative (ER+HER2-) 9.8%; 
ER positive/HER2 positive (ER+HER2+) 18.9%; ER negative/ HER2 positive (ER-HER2+) 34.7%; 
ER negative/HER2 negative (ER-HER2-) 18.8% (Table 2). Taxane chemotherapy was associated 
with a pCR rate of 19.6% compared to 13.3% for non-taxane regimes (p=0.019). In HER2 positive 
patients, the pCR rate was 27.5% in patients who received trastuzumab compared to 14.3% in those 
who did not (p=0.669). No response data were available for the 9 patients treated with neoadjuvant 
hormonal therapy. 
 
Surgical Treatment 
 
Surgery was performed in 94% of stage 3 patients, with 86.6% undergoing mastectomy (as 
primary or secondary procedure), 1.5% having a skin-sparing mastectomy and 6.0% having breast 
conserving surgery. Axillary node clearance was performed in 81.2% of patients; 35.1% had 
positive nodal involvement at pathological review. 
Biological 
Subgroup  
All   
N=344  
ER + HER2 –  
 N=143  
ER + HER2 +  
N=43  
ER – HER2 +  
   N=56  
ER--- HER2 –  
   N=91  
p---value 
(Fishers---Exact)  
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Pathological  
response   
No. assessable  
  
   CR  
   PR  
   NR/PD  
   missing  
  
  
323*  
  
 55  
185  
  63  
  20  
  
  
  
  
18.2  
61.1  
20.8  
  6.2  
  
  
122  
  
   12  
   80  
   30  
     9  
  
  
  
  
  9.8  
65.6  
24.6  
  6.9  
  
  
37  
  
  7  
26  
  4  
  3  
  
  
  
  
18.9  
70.3  
10.8  
  7.5  
  
  
49  
  
17  
28  
  4  
  7  
  
  
  
  
34.7  
57.1  
  8.2  
12.5  
  
  
85  
  
16  
44  
25  
  4  
  
  
  
  
18.8  
51.8  
29.4  
  4.5  
  
ER---HER2--- vs other  
groups  
  
 P=0.7392  
Distant  
metastases  
    Yes  
    No   
    Missing  
  
  
136  
203  
    5  
  
  
40.1  
59.9  
  1.5  
  
  
52  
88  
  3  
  
  
37.1  
62.9  
  2.1  
  
  
11  
30  
  2  
  
  
26.8  
73.2  
  4.7  
  
  
18  
27  
  1  
  
  
40.0  
60.0  
  2.2  
  
  
50  
40  
  1  
  
  
55.6  
44.4  
   1.1  
  
ER---HER2--- vs other  
groups  
P=0.0016  
  
5 yr DRFS %  
(95% C.I)  
  
HR  
p---value  
  
55.2  
(48.8---61.1)  
  
63.1  
(53.1---71.5)  
  
1.23 (0.64, 2.35)  
0.541  
  
  
54.8  
(30.2---73.9)  
  
1.0 (ref cat)  
  
  
57.4  
(40.0---71.4)  
  
1.30 (0.61---2.75)  
0.492  
  
  
38.6  
(27.2---49.7)  
  
2.28 (1.18,4.39)  
0.014  
  
5 yr OS %  
  
(95% C.I) 
HR  
  
  
61.0 %  
(54.8---66.6)  
70.0  
(60.3---77.7)  
  
1.47 (0.69---3.13)  
0.3515  
76.9  
(56.6---88.6)  
  
1.0 (ref.cat)  
66.2   
(49.8---78.3)  
  
1.60 (0.69---3.71)  
0.273  
  
37.7  
(26.6---48.8)  
  
3.22 (1.53---6.80)  
0.002  
  
*Excludes patients who did not receive neoadjuvant chemotherapy, undergo surgery and have  
available data on pathological response  
 
Table 2: Pathological response rates, distant recurrence rates, DRFS and OS of stage 3 patients 
in retrospective review; whole cohort and biological subgroups classified by ER and HER2 
status   
 
 
 
Radiotherapy 
 
All patients treated with breast conserving surgery received breast irradiation, and 93.8% of 
mastectomy patients received radiotherapy to the chest wall. Irradiation of the ipsilateral axilla 
and/or supraclavicular fossa was performed in 15.4% and 52.2% of patients, respectively. 
Data regarding all three treatment modalities (chemotherapy, surgery and radiotherapy) were 
available for 316 patients: 86.4% received trimodality treatment. 
 
Treatment of patients with stage IV disease at presentation 
Data regarding systemic treatment were available for 88 of the 90 patients with evidence of distant 
metastases at presentation: 79.5% (70/88) received chemotherapy (26 had anthracycline based 
chemotherapy; 34 anthracycline/ taxane combination chemotherapy; 5 had taxanes only; 1 had a 
non-anthracycline/ taxane chemotherapy), 6.8% (6/88) received hormonal therapy but not 
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chemotherapy and 13.6% (12/88) received no systemic treatment.  Fifty-five point three per cent 
of the metastatic patients underwent surgery (44/85 had mastectomy and 3/85 had breast 
conserving surgery); no surgery was performed in 44.7% of cases. Radiotherapy to the breast or 
chest wall was performed in 52.4% of metastatic cases (43/82). 
 
 
Follow-up and Survival 
 
Median follow-up was 4.2 years (range 0.2 to 18.2 years). A total of 186 deaths were recorded; 
cause of death was available for 122 patients of whom 109 (89%) died of metastatic breast cancer. 
Median overall survival (OS) was 7.5 years for patients with stage 3 disease at diagnosis, and 1.9 
years for stage 4 disease, with 5-year OS rates of 61.0% and 21.4% respectively (figure 1a). Of 
344 patients with confirmed stage 3 disease at presentation, 136 (40.1%) subsequently developed 
distant metastases with a 5-year DRFS of 55.2% (figure 1b). The most frequent sites of first 
recurrence were liver (40.8%), lung (34.4%), bone (30.4%), brain (23.2%), subcutaneous tissue 
(15.2) and mediastinum (12.8%) with some patients having first recurrence at more than one site. 
Higher rates of CNS recurrence were seen in the ER+HER2+ (27.3%), ER-HER2+ (33.3%), and 
ER- HER2- (20.8%) patients, compared to ER+HER2- (14.9%) cases. Data on locoregional 
recurrence (LLR) post-surgery were available for 237 patients with 50 events reported (21.1%); 44 
LRRs occurred in patients having mastectomies (20.7%), 3 in WLE patients (14.2%), 2 in WLEs 
with completion mastectomies (66.7%) and 1 in a skin sparing mastectomy case (20%). 
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Figure 1: Kaplan-Meier curves illustrating a) overall survival (OS) in stage III and stage IV 
patients; b) distant recurrent free survival (DRFS; stage III patients only; c) OS and d) DRFS in 
stage III patients categorised by ER and HER2 status; e) OS and DRFS and f) in stage III patients 
categorised by complete pathological response and non-complete pathological response to primary 
chemotherapy. 
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When stratified by age, OS (but not DRFS) rate was higher in younger patients (i.e. < 50 y.o.) 
(p=0.01, Table 3).   Five-year OS and DRFS were significantly poorer in ER-HER2- and triple-
negative patients, compared to the other biological subtypes (37.7% OS and 38.6% DRFS vs 76.9% 
OS and 54.8% DRFS for ER+HER2+; 70.0% OS, 63.1% DRFS for ER+HER2- and 66.2% OS and 
57.4% DRFS for ER-HER2+; OS p<0.002 and DRFS p<0.014) (Figure 1 c/d). Pathological complete 
response (pCR), following primary chemotherapy, was associated with a significantly greater 5-year 
OS, compared to those who only achieved a partial response or stable disease (75.1%vs 60.1%, 
p=0.018) (figure 1e). Nodal involvement and vascular invasion (LVI) were also associated with 
poorer DRFS and OS (Table 3). Cox regression multivariate analysis demonstrated that age, triple 
negativity and LVI remained significant independent factors for OS (Table 4). 
 
Thirty two invasive lobular cancers ( ILC) patients were identified in our cohort (~9.4%). Responses 
to chemotherapy in these patients were similar to those observed in the IDC group (p=1.0 in Fisher’s 
exact test). Although not statistically significant, we noted a trend suggesting that lobular histology 
was associated with a worse outcome than ductal histology (HR, 1.58; 95% CI, 0.97-2.59, p=0.069). 
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 OS DRFS 
Hazard 
Ratio 
95% 
Confidence 
Interval 
P 
value 
Hazard 
Ratio 
95% 
Confidence 
Interval 
P 
value 
Age, years       
Age < 50 1.00 
(Reference) 
  1.00 
(Reference) 
  
Age >= 50 1.73 (1.14-2.63) 0.010 1.13 (0.78-1.63) 0.507 
Grade       
Grade 1 1.00   1.00   
Grade 2 1.15 (0.49-2.67) 0.749 0.98 (0.44-2.14) 0.950 
Grade 3 1.14 (0.49-2.63) 0.768 1.05 (0.48-2.30) 0.896 
Multifocal 
disease 
      
No 1.00   1.00   
Yes 1.08 (0.69-1.66) 0.744 1.13 (0.74-1.74) 0.574 
Pathological 
response 
      
CR 1.00   1.00   
NR 3.93 (1.94-7.95) 0.000 3.53 (1.87-6.65) 0.000 
PR 1.78 (0.91-3.49) 0.091 1.62 (0.89-2.93) 0.112 
Nodal status       
Negative 1.00   1.00   
Positive 2.25 (1.39-3.63) 0.001 2.02 (1.29-3.16) 0.002 
Subtypes       
IDC 1.00   1.00   
LOB 1.58 (0.97-2.59) 0.069 1.50 (0.93-2.42) 0.099 
TNBC       
No 1.00   1.00   
Yes 2.11 (1.45-3.08) 0.000 1.74 (1.20-2.53) 0.004 
LVI       
No 1.00   1.00   
Yes 2.24 (1.49-3.37) 0.000 2.03 (1.36-3.02) 0.000 
 
Table 3: Estimates of overall survival (OS) and distant relapse free survival (DRFS) and clinical 
parameters among patients 
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 OS DRFS 
Hazard 
Ratio 
95% 
Confidence 
Interval 
P 
value 
Hazard 
Ratio 
95% 
Confidence 
Interval 
P 
value 
Age group       
Age < 50 Reference   Reference   
Age >= 50 2.14 (1.22-3.75) 0.008 1.26 (0.79-2.00) 0.336 
Pathological 
response 
      
CR Reference   Reference   
NR 2.10 (0.67-6.64) 0.205 2.34 (0.81-6.73) 0.114 
PR 1.21 (0.41-3.56) 0.733 1.25 (0.47-3.34) 0.661 
Nodal status       
Negative Reference   Reference   
Positive 1.97 (0.95-4.11) 0.068 1.63 (0.83-3.23) 0.159 
TNBC       
No Reference   Reference   
Yes 2.49 (1.53-4.04) 0.000 1.82 (1.13-2.93) 0.015 
LVI       
No Reference   Reference   
Yes 1.87 (1.14-3.07) 0.013 1.77 (1.10-2.84) 0.018 
 
 
 
  Table 4: Cox proportional hazards models for OS and DRFS among patients 
 
 
 
 
Discussion 
 
This series represents the largest collection of UK IBC cases published to date, and is the first to 
report the UK incidence of IBC. Our data indicates that IBC accounts for approximately 1% of 
invasive breast cancer cases in the UK suggesting that approximately 500 new cases of IBC are 
diagnosed in the UK each year [16]. Minor variations in incidence figures between participating 
breast cancer units (range 0.4%-1.8%) may reflect different local interpretations of diagnostic 
guidelines in the absence of unique histological identifiers and small absolute numbers involved. 
The figure of 1.0% is slightly lower than US series [2] and may reflect different population 
structures in the UK and US: young black and Hispanic women have an increased risk of IBC, 
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and the UK has a lower population percentage of these groups than the US [17]. Although our 
ethnicity data are not complete, 4.8 % of patients in this series of UK IBC cases were black, 
compared to 1.2% of all UK cases of invasive breast cancer reported in the 2011 National Cancer 
Intelligence Network report [6].  The  Median age at diagnosis in this series was 56 years 
compared to 62 years for unselected UK invasive breast cancer cases (registry data) [6]. The US 
Breast Cancer Surveillance Consortium similarly reported lower age of onset of IBC compared to 
non-IBC or LABC patients (57.3 vs 60.7 years) [17]. The percentage of patients in this series who 
were obese at the time of presentation (41.3%) is higher than studies of non-inflammatory or 
unselected breast cancer (10.3-27.3%, reviewed by Renehan et al.[18])  and is supportive of 
epidemiological studies which indicate that obesity is a significant risk factor for IBC [17]. 
 
Almost one-fifth of patients received antibiotic therapy for presumed infection prior to attending 
the diagnostic breast clinic, highlighting frequent delays in diagnosis of IBC. The observation of a 
measurable mass on sonography in a high proportion of cases is consistent with other series and 
supports recommendations for ultrasound guided core biopsies as the primary diagnostic 
procedure [9,13]. Punch biopsies, which are also recommended in recent UK and US guidelines 
[9,13], were however performed rarely and changes in patient pathways will be required to 
support widespread adoption of this recommendation. As in most other reported IBC series, over 
20% of patients had distant metastases at presentation justifying the UK IBC consortium 
recommendation to perform a staging CT scan at diagnosis [13]. 
 
Pathological profiles were very similar to those reported elsewhere with a higher proportion of ER 
negative tumours and HER2 positive tumours than found in non-IBC [12,17].  
A high proportion of non-metastatic patients identified in our retrospective cohort received 
treatment with neo- adjuvant chemotherapy, surgery and radiotherapy (trimodality treatment) 
[19]. Randomised controlled trial evidence for the optimum chemotherapeutic regimen in IBC, is 
lacking. Previous retrospective series have reported improved pCR rates and overall survival with 
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taxanes [20]. The pCR rate in our cohort was 18.1% which compares well to other published 
series (15.2-18.0%) despite lower use of taxanes here [19,21]. Our data show a higher pCR rate in 
patients receiving taxanes; that this does not reach statistical significance for the overall cohort, or 
for triple negative patients (data not shown) may be due to small absolute numbers. 
 
A small number of IBC patients with lobular histology show trend to worse overall survival when 
compared IDC patients. While most of the previous studies did not specifically compare survival 
data for IDC and ILC patients in IBC, a recent study by Raghav and colleagues found no 
differences between the groups in the 3-year overall survival rates [22]. Examination of larger 
IBC cohorts with carefully defined histological lobular carcinoma subtypes (e.g. the more 
aggressive pleomorphic type which has a less favourable outcome compared versus the classical 
lobular carcinoma) will be necessary to further clarify whether ILC-IBC behaves differently when 
compared to IDC-IBC.    
 
Rates of pCR varied significantly according to biological subtype, with the highest pCR rate in 
HER2+ER- patients, as also reported by Masuda et al.  [19]. As anticipated with >90% of patients 
recruited after 2005, there was high use of neo/adjuvant trastuzumab in this cohort; 86.0% of our 
stage 3 HER2 positive patients receiving this treatment compared to 35.6% of HER2 positive 
patients in the last UK IBC series [23]. In HER2 positive patients, trastuzumab use was associated 
with a higher pCR rate than chemotherapy without trastuzumab (27.5% vs. 14.3%); very small 
numbers in the no-trastuzumab group may explain why this does not reach statistical significance. 
The benefit of neo-adjuvant trastuzumab in IBC was confirmed by the NOAH clinical trial in 
which trastuzumab was associated with a hazard ratio for event-free survival of 0.27 in the IBC 
subgroup (n=63) [24]. Only 3 patients in our series received dual HER2 blockade; this may 
increase in the future given evidence from the NeoSPHERE and NeoALTO trials that pCR rates 
are enhanced by the addition of pertuzumab and lapatinib [25, 26]. 
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Three patients received bevacizumab. Treatment with anti-angiogenic agents is a theoretically 
attractive proposition in IBC given the highly angiogenic nature of these tumours and the 
ARTEMIS trial, of anthracycline/taxane neo-adjuvant chemotherapy with or without 
bevacizumab, included a small number of IBC patients. However, exploratory analysis found no 
benefit from addition of the anti-angiogenic agent in the IBC group [27]. 
 
Most patients underwent mastectomy, however a small number had breast conserving surgery or 
skin-sparing mastectomies. Although US guidelines state that the only surgical procedure to be 
offered for IBC should be a modified radical mastectomy, the recent UK consensus acknowledges 
a paucity of data and suggests that “attempted breast conservation after adequate downstaging can 
be considered based on multidisciplinary review of pre- and post-treatment clinical, radiological 
and pathological features” [9,13]. Earlier data from the Royal Marsden Hospital have shown 
comparable OS rates for patients who did and did not undergo surgery [23], and Bonev et al. 
observed no difference in OS between IBC patients who underwent a modified radical 
mastectomy and those having partial mastectomy [28]. Similarly, in another study no statistically 
significant differences in breast cancer specific survival and OS were observed for patients treated 
with mastectomy or BCS [29]. A recent non-comparative single-centre series describes 35 IBC 
patients treated with BCS and reports locoregional recurrence in 5 cases but followed rapidly by 
distant metastases in 4 of these; the authors suggest that LRR in patients after BCT appears part of 
widespread recurrent disease rather than inadequate local treatment [30]. Analysis of patients in 
our cohort shows no significant difference in OS between patients treated with radical 
mastectomy, versus those having skin sparing or breast conserving surgery, but the number in the 
latter group is very small (n=20) and this result should be treated with caution (supplementary 
Figure 1). Our higher LR recurrence rate in mastectomy patients than BCS patients suggests 
confounding and is difficult to interpret given the amount of missing LR recurrence data in this 
cohort, and small number of BCS cases. 
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Despite use of trimodality treatment in 86.5% of stage III patients, outcomes were still poor with 
40.1% of patients developing distant metastases and a 5-year OS of 61.0% with median survival 
of 7.5 years. The previous largest UK series describing 155 patients with IBC, treated at RMH 
between 1990 and 2007, reported median survival of 45 months in stage 3 patients [23]. Almost 
half of these patients were diagnosed before 1990 and there is significantly less use of 
anthracycline/ taxane chemotherapy in this cohort than in our series. Three contemporary US 
reports contain very similar results to ours (5-year OS of 51%-61%) in patients receiving 
trimodality treatment [12, 31, 32]. Poor outcomes were particularly seen in triple negative 
patients, with a recurrence rate of 56.7%, and a 5-year OS of only 37.7%, similar to the 39.0-
42.7% OS observed elsewhere [12,21]. Patients who achieved a pCR had a significantly better 5-
year OS than non-pathological CR patients, but still developed metastatic disease in 24% of cases. 
 
The high incidence of brain metastases as a first site of metastatic disease in our IBC cohort 
(23%) is similar to that reported in a large American series [11]. Analyses in non-inflammatory 
breast cancer have identified the brain as first site of metastatic disease in <8.0% of cases [33,34]. 
Clinicians treating IBC patients should have a low threshold for suspecting CNS involvement in 
the event of neurological symptoms, particularly in patients with ER negative and/or HER2 
positive disease. 
 
Inevitably, this study is limited by its retrospective nature. All diagnoses of IBC were made 
locally, based on clinical features at the time of presentation. It is not possible to confirm 
definitively that all cases fulfilled all diagnostic criteria for IBC, and highlights the need to collect 
data prospectively, including clinical photographs and imaging data. Biases in patient selection 
may have arisen through the search mechanisms used at some hospitals; some breast units 
searched databases for patients treated with neo-adjuvant chemotherapy to find IBC cases and 
may have missed patients not treated with this modality. As with any retrospective review there is 
missing data; this is not entirely random but determined by availability of data sources which 
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varied significantly from hospital to hospital according to local archiving arrangements of paper 
and electronic patient records. In addition, some missing data points are the result of routine UK 
clinical practice during the earlier years of the study period, for example PR status was not 
routinely tested at many NHS hospitals for much of the study period as testing is not mandated by 
the UK National Institute of Clinical Excellence. However, for many variables there is less 
missing data here than in previous reports based on registry data.  In particular, there is relatively 
little missing HER2 data here compared to series from the SEERS registry which has not 
routinely collected this [17].  
 
 
Summary 
IBC patients represent a small proportion of UK invasive breast cancer cases but have an 
aggressive clinical course with a poor outcome, particularly in patients with triple negative cancer 
and in the majority of patients who do not achieve a complete pathological response to neo-
adjuvant chemotherapy. This study highlights the need for prospective data collection. A UK 
multi-centre prospective study, with biological sampling to facilitate translational research, is now 
in development.   
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Highlights 
• The incidence and behaviour of inflammatory breast cancer (IBC)  in the UK has not 
previously been studied beyond small single centre reviews 
 
• We performed a multi-centre retrospective review of IBC cases from 14 UK and Irish 
hospitals 
 
• IBC cases accounted for 0.4-1.8% of invasive breast cancer cases at these centres 
 
• Despite trimodality  (neoadjuvant chemotherapy/ surgery and radiotherapy) treatment 
in 86.4%, 40.1% of stage III patients developed distant metastases 
 
• Five-year overall survival (OS) was 61.0% for patients with stage III disease at 
presentation 
 
